Synthetic Hormones Market, By Product Type (Steroid Hormones, Peptide Hormone, Amino Acid Derivatives, and Others), By Route of Administration (Oral, Nasal, Subcutaneous, and Intravenous) By Application (Growth Hormone Deficiency, Thyroid Hormone Deficiency, Menopause, Diabetes, and Others) By End User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Synthetic Hormones Market was valued at US$ 21.5 billion in 2024 and is projected to grow at a CAGR of 7.2% to reach US$ 40.6 billion by 2034.

Synthetic hormones represent a crucial category of pharmaceutical compounds designed to mimic the functions of naturally occurring hormones within the human body. Engineered through advanced laboratory processes, these synthetic counterparts are pivotal in addressing hormonal imbalances and deficiencies. The diverse classes of synthetic hormones include steroid hormones, peptide hormones, and amino acid derivatives, each tailored to specific medical applications. Commonly employed to treat conditions such as growth hormone deficiency, thyroid hormone deficiency, and hormonal imbalances associated with menopause or male hypogonadism, synthetic hormones offer targeted therapeutic interventions. Administered through various routes such as oral, nasal, or intravenous, synthetic hormones are distributed through hospital and retail pharmacies, as well as increasingly through online platforms, ensuring accessibility and convenience for patients undergoing hormone replacement therapies or addressing specific endocrine disorders. The continuous advancements in biotechnology and pharmaceutical research contribute to the refinement and expansion of synthetic hormone applications, ushering in new possibilities for personalized and effective healthcare interventions.

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Synthetic Hormones Market Key Drivers:

Increasing incidence of irregular menstrual cycles

• According to the Global Reproductive Health, International Federation of Fertility Societies, 2018, the prevalence of menopausal hot flashes has been increasing in the United States. Around 23 million women in the age group of 45 to 55 years are expected to experience menopausal symptoms like heavy or irregular bleeding, breast tenderness, and hot flashes, which will increase physician visits.
• According to National Center for Biotechnology Information (NCBI), in 2018, the increasing incidence of irregular menstrual cycles has led to an increase in the use of oral contraceptives, birth control pills, birth control shots, vaginal rings, hormonal intrauterine devices (IUD), etc.
• According to the American Thyroid Association (2019), 12% of the U.S. population will develop some kind of thyroid condition in their lifetime, and around 20 million Americans have been diagnosed with some kind of thyroid disorder. These factors are expected to boost the global synthetic hormone market's growth over the forecast period.

Synthetic Hormones Market Restrains:

• According to National Center for Biotechnology Information (NCBI), 2017, some anti-depressants (non-hormonal) such as selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) (paroxetine (Paxil), citalopram (Celexa) and escitalopram (Lexapro)) were reported to show a decrease in severity of hot flashes in menopausal as well as post-menopausal women compared to synthetic hormones.
• The cost-effectiveness of hormonal replacement therapy is one of the important restraining factors. According to NCBI, at least 18 tablets of Vagifem must be used by the patient per month. Therefore, the cost of the medicine per month comes down to $400 – 500 while Paroxetine is to be taken once daily per month, and hence the price of 30 tablets comes down to $50 – 100. Moreover, Paroxetine is available as an oral dose, while Vagifem is a vaginal insert. Hence, patients prefer the oral route of administration over the inserts.

Synthetic Hormones Market is segmented based on Product Type, Route of Administration, Application, End User, and region.

Product Type Insight

• Steroid Hormones: The steroid hormones segment will contribute significantly to the synthetic hormones market over the forecast period. These hormones are crucial in various physiological processes, such as metabolism, immune response, and reproductive functions. Steroid hormones are often used in medical applications, including hormone replacement therapy (HRT) and anti-inflammatory treatments.
• Peptide Hormone: Peptide hormones segment tends to dominate the synthetic hormones market over the forecast period. The dominance of peptide hormones in the global synthetic hormones market, categorized by type, and the increasing prevalence of chronic diseases such as diabetes, which often requires insulin therapy (a peptide hormone), has led to significant demand for these treatments.

Secondly, advancements in biotechnology have improved the efficacy and safety profile of peptide hormones, making them a preferred choice for both patients and healthcare providers. Additionally, the growing understanding and treatment of hormonal deficiencies and the expanding applications of peptide hormones in therapeutic and diagnostic fields have further fueled their market prominence.

• Amino Acid Derivatives: The Amino Acid Derivatives segment will contribute significantly to the synthetic hormones market over the forecast period. Amino acid derivatives are synthetic hormones derived from amino acids, the building blocks of proteins. Thyroid hormones, such as thyroxine, fall into this category. These hormones regulate metabolism, energy production, and overall growth and development.
• Others: The Others category encompasses a diverse range of synthetic hormones that do not fall precisely into the above-mentioned classes. This may include novel hormone analogs, combination therapies, or emerging hormone-related treatments.

Route of Administration Insight

• Oral: The oral route of administration will contribute significantly to the synthetic hormones market over the forecast period. Oral administration involves delivering synthetic hormones through the mouth, typically in tablets or capsules. This route is convenient and patient-friendly, promoting high adherence to treatment regimens.
• Nasal: The nasal route of administration will contribute significantly to the synthetic hormones market over the forecast period. Nasal administration involves delivering synthetic hormones through the nasal mucosa using sprays, drops, or powders. This route offers a noninvasive alternative to injections and allows for rapid absorption into the bloodstream.
• Subcutaneous: The subcutaneous route of administration dominates the synthetic hormones market due to its advantages in terms of efficacy, convenience, and patient compliance. Subcutaneous injections allow for the direct delivery of synthetic hormones into the fatty tissue beneath the skin, ensuring a more controlled and sustained release of the medication into the bloodstream. This method is particularly advantageous for long-term treatments, such as hormone replacement therapy, and chronic conditions, such as diabetes, where regular dosing is essential.
• Intravenous: The intravenous route of administration will contribute significantly to the synthetic hormones market over the forecast period. Intravenous (IV) administration involves directly injecting synthetic hormones into the bloodstream through a vein. This route ensures immediate and complete bioavailability, making it suitable for critical or emergencies.

Application Insight

• Diabetes: Diabetes segment tends to dominate the synthetic hormones market over the forecast period. This trend is primarily driven by the escalating global prevalence of diabetes, particularly Type 1 and advanced Type 2, which require insulin therapy. Insulin, a critical synthetic hormone for diabetes management, has seen a surge in demand due to the growing diabetic population, increased awareness, and better diagnostic practices, which have led to earlier and more frequent treatment initiation.
• Growth Hormone Deficiency: The growth Hormone Deficiency segment contributes significantly to the synthetic hormones market over the forecast period. Artificial growth hormones are administered to address the deficiency when the pituitary gland fails to produce sufficient growth hormone, leading to stunted growth in children and a range of metabolic issues in adults, promoting average growth and development in pediatric patients and addressing metabolic imbalances in adults.
• Thyroid Hormone Deficiency: Thyroid Hormone Deficiency will significantly contribute to the synthetic hormones market over the forecast period. Synthetic thyroid hormones, such as levothyroxine, are commonly prescribed to replace or supplement the body's thyroid hormone levels. This helps regulate metabolism, energy levels, and overall physiological functions.
• Menopause: Menopause tends to be fastest growing in synthetic hormones market over the forecast period. Hormone replacement therapy (HRT) involving synthetic hormones is often prescribed to manage menopausal symptoms such as hot flashes, mood swings, and bone density loss. Estrogen and progestin formulations are commonly used in HRT to alleviate these symptoms.
• Others: The Others category encompasses a diverse range of applications for synthetic hormones that may not fit into the specific categories mentioned above. This could include emerging areas of hormone therapy, innovative treatments for rare disorders, or applications outside the traditional scope of hormone replacement.

End User Insights

• Hospital Pharmacies: The hospital pharmacies segment accounted for the largest share of the synthetic hormones market over the forecast period. This is due to their critical role in providing comprehensive healthcare services. Hospital pharmacies are integral to the healthcare system, ensuring the availability and management of various medications, including synthetic hormones.
• Their proximity to diagnostic and treatment centers enables immediate and coordinated care, particularly vital for conditions requiring hormone therapies. Hospitals often deal with acute and severe cases where immediate hormone therapy, such as insulin for diabetes or emergency hormonal treatments, is essential.
• Retail Pharmacies: The retail pharmacies segment contributes significantly to the synthetic hormones market over the forecast period. Retail pharmacies cater to the broader public, offering convenient access to synthetic hormones for individuals with prescriptions. Patients can obtain hormone medications from retail pharmacies, ensuring accessibility for those undergoing long-term treatments or hormone replacement therapies.
• Online Pharmacies: The online pharmacies segment will contribute significantly to the synthetic hormones market over the forecast period. The rise of online pharmacies has transformed the distribution landscape for synthetic hormones. Patients can order hormone medications through online platforms, often providing convenience, discretion, and potential cost savings.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

Synthetic Hormones Market Regional Insights

• The North American market is estimated to witness a significantly high revenue share over the forecast period, owing to the widespread presence of several key manufacturers and a large customer base. Moreover, key players are engaged in the development and introduction of generic products in the region. Increasing incidences of hormonal imbalance across regions are expected to boost the global synthetic hormones market over the forecast period. For instance, Teva Pharmaceutical Industries Ltd., launched generic version of Vagifem (estradiol vaginal inserts) in the U.S. in July 2019 which is indicated for the treatment of atrophic vaginitis in menopausal women.
• The Asia Pacific market is estimated to witness the fastest revenue share due to the large population base, increasing disposable income, and changing lifestyles contributing to the rising incidence of hormonal disorders. China and India are the key markets for the Synthetic Hormones Market in the region over the forecast period.
• Europe: Europe also plays a key role in the synthetic hormones market. Countries like Germany, the UK, and France have a robust pharmaceutical industry and are witnessing an increase in the aging population. The prevalence of hormone-related disorders and the demand for innovative treatment options contribute to market growth in this region.
• Latin America: Latin America has a developing healthcare sector, and the synthetic hormones market is expected to grow steadily. Increased awareness about hormonal disorders and their treatment options drives market growth in the region.
• Middle East & Africa: The Middle East and Africa show varying degrees of market development. Factors such as improving healthcare infrastructure, rising awareness, and increasing investment in healthcare contribute to market growth.

Report Scope:                    

Attribute	Details
Market Size 2024	US$ 21.5 billion
Projected Market Size 2034	US$ 40.6 billion
CAGR Growth Rate	7.2%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Product Type -  Steroid Hormones, Peptide Hormone, Amino Acid Derivatives, and Others By Route of Administration -  Oral, Nasal, Subcutaneous, and Intravenous By Application -  Growth Hormone Deficiency, Thyroid Hormone Deficiency, Menopause, Diabetes, and Others By End User - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study, has segmented the Synthetic Hormones Market report based on Product Type, Route of Administration, Application, End User and region:

 Synthetic Hormones Market, By Product Type:

• Steroid Hormones
• Peptide Hormone
• Amino Acid Derivatives
• Others

Synthetic Hormones Market, By Route of Administration:

• Oral
• Nasal
• Subcutaneous
• Intravenous

Synthetic Hormones Market, By Application:

• Growth Hormone Deficiency
• Thyroid Hormone Deficiency
• Menopause
• Diabetes
• Others

Synthetic Hormones Market, By End User:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Synthetic Hormones Market, By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Synthetic Hormones Market includes, Pfizer Inc., McGuff Pharmaceuticals, Inc., Lyndra Therapeutics, Inc., Ferring B.V., Slayback Pharma LLC, American Regent, Inc., Endo Pharmaceuticals Inc., IBSA Institute Biochimique SA, Acerus Pharmaceuticals Corporation, and Lupin Pharmaceuticals, Inc.

Recent Development:

• In March 2024, the first over-the-counter birth control pill, Opill, will be available in U.S. stores, allowing American women and teens to purchase contraceptive medication as quickly as they buy aspirin. According to the company's suggested retail price, a one-month supply will cost about $20 and a three-month supply will cost around $50. It will also be sold online. Opill is an older class of contraceptive, sometimes called minipills, that contain a single synthetic hormone, progestin, and generally carry fewer side effects than more popular combination estrogen and progestin pills.
• In April 2023, Mankind Pharma geared up to take on one of Abbott India's top selling synthetic hormone brands Duphaston (dydrogesterone) by setting up a dedicated factory in Udaipur, Rajasthan, capable of end-to-end manufacturing of the drug that is widely used for preventing miscarriage and treating infertility.

• Pfizer Inc.*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• McGuff Pharmaceuticals, Inc.
• Lyndra Therapeutics, Inc.
• Ferring B.V.
• Slayback Pharma LLC
• American Regent, Inc.
• Endo Pharmaceuticals Inc.
• IBSA Institute Biochimique SA
• Acerus Pharmaceuticals Corporation
• Lupin Pharmaceuticals, Inc.

“*” marked represents similar segmentation in other categories in the respective section.